Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D).

Authors

Dong Shen

Janssen Research and Development, Spring House, PA

Dong Shen , Shibu Thomas , Florence Lefresne , Michael Gormley , Karen Urtishak , Marjolein Lahaye , Bertrand F. Tombal , Axel S Merseburger , Trilok V. Parekh , Deborah S. Ricci , Gerhardt Attard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).

First Author: Vivek Narayan

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A randomized phase II trial of abiraterone, olaparib or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.

First Author: Zachery Reichert

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.

First Author: Mehmet Asim Bilen

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

First Author: Shahneen Sandhu